LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

Slides:

Advertisements

Similar presentations

Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors

Advertisements

Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.

Guide to OncoLnc: A new TCGA data portal

Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.

Supplementary Figure 1 A B C.

A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716

C Supplemental Figure S2.. C Supplemental Figure S2.

Hallett, et al., - Supplementary Figure 1

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

Figure S1. DCYTB expression is higher in ER+ than ER- patients

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

A B C Supplementary figure S7

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Fig. 2 LYM attractor metagene.

(A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza) for 4 d. (A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza)

PPARγ signaling correlates with LATS2 in human and mouse tumors and promotes cell death in a LATS2-dependent manner. PPARγ signaling correlates with LATS2.

Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities Martin Lauss, Jeremie Nsengimana, Johan Staaf, Julia Newton-Bishop, Göran.

Human triple‐negative breast cancers (TNBC) express WNT10B, show active Wnt signalling and have high proliferation, and WNT10B has clinical relevance and.

Volume 5, Issue 4, Pages e5 (October 2017)

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Volume 23, Issue 11, Pages (June 2018)

(A) Hierarchical clustering was performed to identify groups of patients with similar RNASeq expression of 20 genes associated with reduced survivability.

LATS2 is a tumor suppressor in a mouse lumB breast cancer model.

(A) Schematic representation of the conditional Lats1 locus.

Deletion of Lats1 is phenotypically distinct from Lats2 deletion in PyMT tumors. Deletion of Lats1 is phenotypically distinct from Lats2 deletion in PyMT.

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

JNK signature in breast cancer cells is linked to ECM, stem cell, and wound healing gene networks and is enriched in basal‐like breast cancer JNK signature.

Volume 17, Issue 8, Pages (November 2016)

Volume 21, Issue 8, Pages (November 2017)

Volume 5, Issue 1, Pages 1-9 (July 2015)

(A) Genotyping of the Lats2 and Cre alleles in the PyMT-derived cell lines (see primers location in Fig S2A). (A) Genotyping of the Lats2 and Cre alleles.

Supplementary Figure 1 A B C.

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

Robustness of TRU, Proximal-proliferative (PP), and Proximal-inflammatory (PI) classification. Robustness of TRU, Proximal-proliferative (PP), and Proximal-inflammatory.

DNMT3A1 signatures are not recapitulated in AML.

DNMT3A2 signatures are coherently modified in AML.

Metascape Tripathi et al 2015pathways enrichment analysis (Tripathi et al 2015, of differentially expressed genes (counts > 5, FC.

(A) Schematic representation of the conditional Lats2 locus.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Expression of RUNX2 correlates with ER/PR/HER2-negative human breast cancer. Expression of RUNX2 correlates with ER/PR/HER2-negative human breast cancer.

Correlation between Pten/p53 status and AKT pathway activity in BC and effect on clinical outcome Box plot for p53‐pathway activity in p53 wild‐type and.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Extended analysis of differential expression datasets.

(A) Relative expression levels of the top most down-regulated genes in LATS2L breast tumors (TCGA-BRCA dataset, see Fig 1) in the panel of breast cancer.

Fig. 2 LYM attractor metagene.

LATS2 augments oxidative phosphorylation.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Ki-67 expression is determined by the cell-cycle stage.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

by Wei-Yi Cheng, Tai-Hsien Ou Yang, and Dimitris Anastassiou

EN1 expression in breast cancer and clinical outcome.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

Clustering analysis of DTC-associated genes.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Frequently mutated genes in colorectal cancer.

Kaplan-Meier table analysis of patients with corticobasal degeneration after onset of symptoms; the y axis refers to proportion of patients who are alive.

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.

MYC and LYN are coexpressed and have interdependent clinical outcomes.

Gene expression heatmap of non–T-cell-inflamed, intermediate, and T-cell–inflamed testicular germ cell tumors from TCGA. Genes are on the row, and samples.

Subtype classification of breast functional screening results.

Volume 28, Issue 4, Pages e6 (July 2019)

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. (A) Scatter plot of LATS1 and LATS2 expression levels in breast cancer tumors (TCGA-BRCA dataset). Pearson’s correlation coefficient 0.44. A cutoff of the 20% of tumors expressing the lowest levels of each LATS gene was used to divide the tumors into three groups: LATS1L, LATS2L, and LATSL, compared with LATSH. (B) Heatmap depicting the expression levels of a 20-gene LATS2L signature (the 20 most down-regulated genes exclusively in LATS2L tumors, compared with LATSH tumors; see Table S4 and the Materials and Methods section) in breast tumors (TCGA-BRCA) sorted according to PAM50 subtype classification. (C) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, TCGA-BRCA); ***P-value < 0.001, t test comparing lumB tumors with all other subtypes. Number of tumors of each subtype is indicated at the bottom. (D) Kaplan-Meier analysis of survival probability of luminal breast cancer patients (METABRIC dataset, n = 1139; Cox proportional hazards model) divided according to expression levels of the LATS2L signature (as in B). Noa Furth et al. LSA 2018;1:e201800171 © 2018 Furth et al.